18.06.2010 • NewsDSMcooperation

DSM To Manufacture C. Difficile Compound for Novacta Biosystems

DSM BioSolutions has announced that it has entered into an agreement with Novacta Biosystems, Welwyn Garden City, UK, for the process development and cGMP production of its C. difficile molecule, a new class of lantibiotic compounds.

DSM has successfully completed the process development and commenced cGMP-manufacturing of the Novacta compound at its microbial fermentation biotech facility located in Capua, Italy. The product will initially be used for pre-clinical and phase I clinical trials. DSM's Capua facility is uniquely equipped for the production of biologically active compounds produced via microbial fermentation and has extensive experience in both bacterial and fungal fermentation.

No financial terms will be disclosed.

Company

Royal DSM N.V.


6401 JH Heerlen

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

CHEManager Spotlight

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics
Creating Interfaces

Standardization and Harmonization of Digital Chemical and Pharmaceutical Logistics

CHEManager Spotlight is an exclusive event tailored for practitioners and decision-makers in the chemical industry. This part of our event series delves into the latest trends and innovations in logistics to streamline your operations and drive efficiency.